CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 44 enrolled
Drug / intervention
Ergocalciferoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03747523
NCT03747523Early Ph 1Completed
CompareCT.gov

Study of the Effect of Ergocalciferol on Plasma and Urinary Mucin-1 Levels in Healthy Individuals and Individuals With Autosomal Dominant Tubulo-Interstitial Kidney Disease Due to MUC1 Mutations (ADTKD-MUC1)

Wake Forest University Health Sciences·interventional·Posted Nov 20, 2018·Updated Oct 29, 2020

In Brief

A Early Phase 1 clinical trial evaluating Ergocalciferol for Ergocalciferol. Completed, enrolled 44 participants across 1 site.

Detailed Summary

To determine if a one-time oral administration of ergocalciferol results in a decline in plasma mucin-1 levels in healthy individuals and individuals with ADTKD-MUC1.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErgocalciferol
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedNov 20, 2018
Enrollment StartMar 12, 2019
Primary CompletionDec 20, 2019
Study CompletionJan 27, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.6 years ago

Interventions

Ergocalciferoldrug

Investigational drug will be administered to eligible participants in a single dose of 200,000 USP units vitamin D